Fusion Antibodies (LSE:FAB) PEG Ratio: N/A (As of Jul. 05, 2026)


LSE:FAB Fusion Antibodies PLC LSE:FAB
33 GF Score
Price £0.12
GF Value £0.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fusion Antibodies PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Fusion Antibodies's PE Ratio without NRI is 0.00. Fusion Antibodies's 5-Year EBITDA growth rate is -6.90%. Therefore, Fusion Antibodies's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Fusion Antibodies's PEG Ratio or its related term are showing as below:



LSE:FAB's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.03
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Fusion Antibodies  (LSE:FAB) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Fusion Antibodies PEG Ratio Related Terms


Fusion Antibodies PEG Ratio Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies PEG Ratio Chart

Fusion Antibodies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LSE:FAB vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Fusion Antibodies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's PEG Ratio falls into.


LSE:FAB
33GF Score
Fusion Antibodies PLC LSE:FAB
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fusion Antibodies PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Fusion Antibodies's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-6.90
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.12 is trading 200% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

  • PEG Ratio: N/A
  • GF Value™: £0.04 vs. price of £0.12 (200% above fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score

Get the complete analysis for LSE:FAB

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12
Price
£0.04
GF Value